Biotech/Pharmaceutical Raheel Farooq
Will MS Portfolio Support Biogen in Future?
The biotech has to take assertive measures and seek other therapeutic fields such as oncology and hematology to overcome the revenue decline in the near future
MORE ARTICLE ON THIS SECTOR
August 2, 2016 at 1:48 pm
Amgen and Advaxis Step Ahead to Develop ADXS-NEO
The deal will have an exceptional impact on Amgen’s drug portfolio and will increase its patient pool
August 2, 2016 at 12:15 pm
Will Celgene's Dependency on Abraxane Turn Fruitful?
The biotech has to look for other options to cover the drugs maturation resulting in revenue decline
August 1, 2016 at 2:43 pm
Shire Goes Deeper into Hemophilia Segment
With the approval of the reconstitution system, the company’s hemophilia portfolio will be able to capture more patient pool
August 1, 2016 at 12:01 pm
GlaxoSmithKline Picks Alphabet for Bioelectronic Medici...
The joint venture will play vital role in the research and development of bioelectronic medicine in order to sort out the treatment of multiple ailmen...
August 1, 2016 at 5:57 am
AstraZeneca: What Are the Future Prospects?
The drug maker is yet to sort out multiple segments to make its drug pipeline more robust and competitive
July 26, 2016 at 5:17 pm
Will Biogen Continue to Gain from Tecfidera This Year?
Biogen has to work on its drug pipeline to overcome the decline in Tecfidera’s sales due to the drug’s association with PML
Subscribe to our mailing list to get the updates your email inbox.
July 25, 2016 at 4:06 pm EST
Copyright © 2015 Business Finance News